122 related articles for article (PubMed ID: 10470429)
1. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes.
Maraveyas A; Baban B; Kennard D; Rook GA; Westby M; Grange JM; Lydyard P; Stanford JL; Jones M; Selby P; Dalgleish AG
Ann Oncol; 1999 Jul; 10(7):817-24. PubMed ID: 10470429
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
[TBL] [Abstract][Full Text] [Related]
4. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
5. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM; Schneble EJ; Jackson DO; Hale DF; Vreeland TJ; Flores M; Martin J; Herbert GS; Hardin MO; Yu X; Wagner TE; Peoples GE
Cancer Immunol Immunother; 2016 Apr; 65(4):383-92. PubMed ID: 26894495
[TBL] [Abstract][Full Text] [Related]
6. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits.
Seledtsova GV; Shishkov AA; Kaschenko EA; Goncharov AG; Gazatova ND; Seledtsov VI
Eur J Dermatol; 2016 Apr; 26(2):138-43. PubMed ID: 27026566
[TBL] [Abstract][Full Text] [Related]
7. Xenovaccinotherapy for melanoma.
Seledtsov VI; Shishkov AA; Surovtseva MA; Samarin DM; Seledtsova GV; Niza NA; Seledtsov DV
Eur J Dermatol; 2006; 16(6):655-61. PubMed ID: 17229606
[TBL] [Abstract][Full Text] [Related]
8. Xenovaccinotherapy for colorectal cancer.
Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
[TBL] [Abstract][Full Text] [Related]
9. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
[TBL] [Abstract][Full Text] [Related]
13. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.
Lee P; Wang F; Kuniyoshi J; Rubio V; Stuges T; Groshen S; Gee C; Lau R; Jeffery G; Margolin K; Marty V; Weber J
J Clin Oncol; 2001 Sep; 19(18):3836-47. PubMed ID: 11559721
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.
Cananzi FC; Mudan S; Dunne M; Belonwu N; Dalgleish AG
Hum Vaccin Immunother; 2013 Nov; 9(11):2427-33. PubMed ID: 23863507
[TBL] [Abstract][Full Text] [Related]
18. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.
Marshall JA; Forster TH; Purdie DM; Lanagan CM; O'Connor LE; O'Rourke MG; Johnson MK; See JL; Ellem KA; Martinez NR; López JA; Schmidt CW
Immunol Cell Biol; 2006 Jun; 84(3):295-302. PubMed ID: 16681827
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
[TBL] [Abstract][Full Text] [Related]
20. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
Kyte JA; Gaudernack G; Dueland S; Trachsel S; Julsrud L; Aamdal S
Clin Cancer Res; 2011 Jul; 17(13):4568-80. PubMed ID: 21586625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
